Search
Opening hours

Vilnius

S. Žukausko g. 19
Opening hours:
I-V 07:30 - 20:30
VI 09:00 - 15:00
VII --

Kaunas

Miško g. 25A
Opening hours:
I-V 08:00 - 20:00
VI 09:00 - 15:00
VII --

Klaipėda

Dragūnų str. 2
Opening hours:
I-V 08:00 - 20:00
VI, VII --
Naujoji Uosto g. 9
Opening hours:
I-V 08:00 - 20:00
VI 09:00 - 15:00
VII --

Kretinga

J. Basanavičiaus str. 80
Opening hours:
I-V 08:00 - 20:00
VI, VII --
 
Opening hours E-shop About health
Search
+370 633 30 303
Registration
In Vilnius In Kaunas In Klaipėda
+370 633 30 303 Online registration
Home / Doctors / Rheumatologists / Assoc. Prof. Dr. Vilija OKĖ
Book Online

Assoc. Prof. Dr. Vilija OKĖ

Rheumatologist

Areas of expertise:
Psoriatic arthritisRheumatoid arthritisSpondyloarthropathiesSystemic and cutaneous lupus erythematosus (SLE, CLE)Skin inflammation associated with rheumatic diseasesPolymyalgia rheumaticaFibromyalgiaDegenerative joint diseasesEpicondylitis, trochanteritis, trigger finger, carpal tunnel syndrome, etc.
Languages:LT / EN / SV / RU
Workplace:

Klaipėda, Naujoji Uosto g. 9

Book Online

Biography

Education
  • 2003 – Master’s degree in Medicine and qualification as a medical doctor, Kaunas University of Medicine
  • 2005–2011 – Doctoral studies at the Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden
  • 2008–2015 – Rheumatology residency at Karolinska University Hospital, Stockholm, Sweden
  • 2011 – PhD in Medical Sciences, Rheumatology Unit, Faculty of Medicine, Karolinska Institutet, Stockholm, Sweden
Professional experience
  • 2015–2019 – Rheumatologist at Karolinska University Hospital, Stockholm, Sweden.
  • 2017 – Research fellowship at Mayo Clinic, Rochester, Minnesota, USA.
  • 2019–2026 – Senior Specialist in Rheumatology at the Rheumatology Center, Academic Specialist Center, Stockholm, Sweden.
  • Since 2023 – Associate Professor of Rheumatology at the Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Professional development
  • European League Against Rheumatism (EULAR) congresses and scientific presentations: Copenhagen, Denmark (2022); Milan, Italy (2023).
  • American College of Rheumatology (ACR) congresses and scientific presentations: San Diego, California, USA (2017); Boston, Massachusetts, USA (2007).
  • World Lupus Congress congresses and scientific presentations: Melbourne, Australia (2017); Toronto, Canada (2025).
  • European Lupus Meeting (SLEuro) congresses and scientific presentations: Venice, Italy (2016); Düsseldorf, Germany (2018); Stockholm, Sweden (2022); Bruges, Belgium (2024); Lisbon, Portugal (2026).
Scientific and educational activities
  • Lectin pathway of complement in SLE: MAP-1 as a marker of haematological manifestations and elevated type I interferon activity. Lindelöf L, Garred P, Hong MG, Wahl Vælum S, Holten Petersen L, Leonard D, Sayadi A, Oke V, Niewold TB, Diaz-Gallo LM, Saevarsdottir S, Gunnarsson I, Svenungsson E, Eriksson O. Lupus Sci Med. 2026 Apr 9;13(1):e001890.
  • CD72 downregulation on DN2 B cells is associated with disease activity and resistance to rituximab in systemic lupus erythematosus. Wangriatisak K, Huang W, Sechi G, Oke V, Chemin K, Grönwall C, Gunnarsson I, Malmström V, Faustini F. Rheumatology (Oxford). 2026 Mar 5;65(3):keag097.
  • Guselkumab Improves Patient-Reported Outcomes Among Participants with Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors in the COSMOS Study. Gossec L, Baraliakos X, Galloway J, Oke V, Sfikakis P, Rampakakis E, Sharaf M, Lavie F, McInnes IB. Rheumatol Ther. 2026 Apr;13(2):347-360.
  • Interleukin 16 in lupus nephritis-a role for Th1 and CD8+ T cell migration. Wangriatisak K, Faustini F, Filipovic M, Wähämaa H, Malmström V, Gunnarsson I, Oke V. Clin Exp Immunol. 2025 Jan 21;219(1):uxaf068.
  • Role of interleukin-16 in human diseases: a novel potential therapeutic target. Niewold TB, Lehman JS, Gunnarsson I, Meves A, Oke V. Front Immunol. 2025 Jun 2;16:1524026. doi: 10.3389/fimmu.2025.1524026. eCollection 2025.
  • Janus kinase inhibitors enhance prostanoid biosynthesis in human whole blood in vitro: implications for cardiovascular side effects and prevention strategies. Alabbasi S, Tacconelli S, de Vries M, Gunnarsson I, Oke V, Kvarnström M, De Michele A, Gregorio PD, Patrignani P, Idborg H, Jakobsson PJ. Ann Rheum Dis. 2025 Sep;84(9):1549-1560.
  • Anti-histone and anti-nucleosome rather than anti-dsDNA antibodies associate with IFN-induced biomarkers in Sudanese and Swedish SLE patients. Elbagir S, Mohammed NA, Oke V, Larsson A, Nilsson J, Elshafie A, Elagib EM, Nur MAM, Gunnarsson I, Svenungsson E, Rönnelid J. Rheumatology (Oxford). 2025 Mar 1;64(3):1170-1178.
  • Interleukin (IL) 16: a candidate urinary biomarker for proliferative lupus nephritis. Häyry A, Faustini F, Zickert A, Larsson A, Niewold TB, Svenungsson E, Oke V, Gunnarsson I. Lupus Sci Med. 2022 Sep;9(1):e000744.
  • Cytokines as Biomarkers in Systemic Lupus Erythematosus: Value for Diagnosis and Drug Therapy. Idborg H, Oke V. Int J Mol Sci. 2021 Oct 20;22(21):11327.
  • Four Systemic Lupus Erythematosus Subgroups, Defined by Autoantibodies Status, Differ Regarding HLA-DRB1 Genotype Associations and Immunological and Clinical Manifestations. Diaz-Gallo LM, Oke V, Lundström E, Elvin K, Ling Wu Y, Eketjäll S, Zickert A, Gustafsson JT, Jönsen A, Leonard D, Birmingham DJ, Nordmark G, Bengtsson AA, Rönnblom L, Gunnarsson I, Yu CY, Padyukov L, Svenungsson E. ACR Open Rheumatol. 2022 Jan;4(1):27-39.
  • Proteome study of cutaneous lupus erythematosus (CLE) and dermatomyositis skin lesions reveals IL-16 is differentially upregulated in CLE. Niewold TB, Meves A, Lehman JS, Popovic-Silwerfeldt K, Häyry A, Söderlund-Matell T, Charlesworth CM, Madden B, Lundberg IE, Wahren-Herlenius M, Svenungsson E, Oke V. Arthritis Res Ther. 2021 Apr 30;23(1):132.
  • Interferon activation status underlies higher antibody response to viral antigens in patients with systemic lupus erythematosus receiving no or light treatment. Björk A, Da Silva Rodrigues R, Richardsdotter Andersson E, Ramírez Sepúlveda JI, Mofors J, Kvarnström M, Oke V, Svenungsson E, Gunnarsson I, Wahren-Herlenius M. Rheumatology (Oxford). 2021 Mar 2;60(3):1445-1455.
  • Sjögren Syndrome in Systemic Lupus Erythematosus: A Subset Characterized by a Systemic Inflammatory State. Ruacho G, Kvarnström M, Zickert A, Oke V, Rönnelid J, Eketjäll S, Elvin K, Gunnarsson I, Svenungsson E. J Rheumatol. 2020 Jun 1;47(6):865-875.
  • Circulating Levels of Interferon Regulatory Factor-5 Associates With Subgroups of Systemic Lupus Erythematosus Patients. Idborg H, Zandian A, Ossipova E, Wigren E, Preger C, Mobarrez F, Checa A, Sohrabian A, Pucholt P, Sandling JK, Fernandes-Cerqueira C, Rönnelid J, Oke V, Grosso G, Kvarnström M, Larsson A, Wheelock CE, Syvänen AC, Rönnblom L, Kultima K, Persson H, Gräslund S, Gunnarsson I, Nilsson P, Svenungsson E, Jakobsson PJ. Front Immunol. 2019 May 17;10:1029. doi: 10.3389/fimmu.2019.01029.
  • High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. Oke V, Gunnarsson I, Dorschner J, Eketjäll S, Zickert A, Niewold TB, Svenungsson E. Arthritis Res Ther. 2019 Apr 29;21(1):107.
  • TNF-α and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus. Idborg H, Eketjäll S, Pettersson S, Gustafsson JT, Zickert A, Kvarnström M, Oke V, Jakobsson PJ, Gunnarsson I, Svenungsson E. Lupus Sci Med. 2018 Jun 4;5(1):e000260.
  • IFN-λ1 with Th17 axis cytokines and IFN-α define different subsets in systemic lupus erythematosus (SLE). Oke V, Brauner S, Larsson A, Gustafsson J, Zickert A, Gunnarsson I, Svenungsson E. Arthritis Res Ther. 2017 Jun 15;19(1):139.
  • Interferon (IFN)-λ is a potential mediator in lupus nephritis. Zickert A, Oke V, Parodis I, Svenungsson E, Sundström Y, Gunnarsson I. Lupus Sci Med. 2016 Nov 22;3(1):e000170.
  • The immunobiology of Ro52 (TRIM21) in autoimmunity: a critical review. Oke V, Wahren-Herlenius M. J Autoimmun. 2012 Aug;39(1-2):77-82.
  • Photoprovocation in cutaneous lupus erythematosus: a multicenter study evaluating a standardized protocol. Kuhn A, Wozniacka A, Szepietowski JC, Gläser R, Lehmann P, Haust M, Sysa-Jedrzejowska A, Reich A, Oke V, Hügel R, Calderon C, de Vries DE, Nyberg F. J Invest Dermatol. 2011 Aug;131(8):1622-30.
  • High Ro52 expression in spontaneous and UV-induced cutaneous inflammation. Oke V, Vassilaki I, Espinosa A, Strandberg L, Kuchroo VK, Nyberg F, Wahren-Herlenius M. J Invest Dermatol. 2009 Aug;129(8):2000-10.
  • The autoantigen Ro52 is an E3 ligase resident in the cytoplasm but enters the nucleus upon cellular exposure to nitric oxide. Espinosa A, Oke V, Elfving A, Nyberg F, Covacu R, Wahren-Herlenius M. Exp Cell Res. 2008 Dec 10;314(20):3605-13.
  • Translocation of the novel cytokine HMGB1 to the cytoplasm and extracellular space coincides with the peak of clinical activity in experimentally UV-induced lesions of cutaneous lupus erythematosus. V. (Oke) Barkauskaite, M Ek, K Popovic, H E Harris, M Wahren-Herlenius, F Nyberg. Lupus. 2007;16(10):794-802.
Memberships
  • Swedish Rheumatology Association

About health

All articles about health
All articles
In Vilnius S. Žukausko g. 19 +370 5 264 4466 Internetu